BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 7, 2020
Product Development

WuXi AppTec’s Yang on COVID-19 pushing the gates open on data sharing: a BioCentury audio interview

WuXi AppTec’s Steve Yang says the collaborations taking place during COVID-19 could not only open the door to more data sharing, but lay the groundwork for understanding which assays have the most translational...
BioCentury | Aug 11, 2020
Product Development

Charting a path to COVID-19 testing that supports a return to normalcy

A panel of diagnostics leaders points to open questions and infrastructure gaps limiting what society is getting out of COVID-19 testing, and how the lessons learned could reach beyond the pandemic. In an Aug. 5 webinar,...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

The April deal between Arrakis and Roche started with dinner in Basel and closed over Zoom. In a podcast conversation with BioCentury, the architects of the deal, James Sabry and Michael Gilman, describe how the...
BioCentury | Mar 7, 2020
Politics, Policy & Law

Coronavirus crisis calls for competence, clarity and courage at the top

In times of crisis, societies need competence, clarity and courage from their leaders -- qualities that have been in short supply during the COVID-19 outbreak. Now more than ever, agencies like CDC and FDA need...
BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

Though often compared to Moderna, BioNTech is not an mRNA company -- it’s a cancer company. The German biotech has amassed six different technologies in its 12-year history to address the entire continuum of solid...
BioCentury | Oct 24, 2019
Tools & Techniques

Driving safely into solid tumors with CAR exosomes

Therapeutic exosomes derived from CAR T cells could avoid the cytotoxic side effects of the engineered cells and overcome barriers in the tumor microenvironment that limit the cells’ efficacy. The obstacles to deploying CAR T...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
Items per page:
1 - 10 of 139
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 7, 2020
Product Development

WuXi AppTec’s Yang on COVID-19 pushing the gates open on data sharing: a BioCentury audio interview

WuXi AppTec’s Steve Yang says the collaborations taking place during COVID-19 could not only open the door to more data sharing, but lay the groundwork for understanding which assays have the most translational...
BioCentury | Aug 11, 2020
Product Development

Charting a path to COVID-19 testing that supports a return to normalcy

A panel of diagnostics leaders points to open questions and infrastructure gaps limiting what society is getting out of COVID-19 testing, and how the lessons learned could reach beyond the pandemic. In an Aug. 5 webinar,...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | May 9, 2020
Deals

The Roche-Arrakis deal in their own words

The April deal between Arrakis and Roche started with dinner in Basel and closed over Zoom. In a podcast conversation with BioCentury, the architects of the deal, James Sabry and Michael Gilman, describe how the...
BioCentury | Mar 7, 2020
Politics, Policy & Law

Coronavirus crisis calls for competence, clarity and courage at the top

In times of crisis, societies need competence, clarity and courage from their leaders -- qualities that have been in short supply during the COVID-19 outbreak. Now more than ever, agencies like CDC and FDA need...
BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

Though often compared to Moderna, BioNTech is not an mRNA company -- it’s a cancer company. The German biotech has amassed six different technologies in its 12-year history to address the entire continuum of solid...
BioCentury | Oct 24, 2019
Tools & Techniques

Driving safely into solid tumors with CAR exosomes

Therapeutic exosomes derived from CAR T cells could avoid the cytotoxic side effects of the engineered cells and overcome barriers in the tumor microenvironment that limit the cells’ efficacy. The obstacles to deploying CAR T...
BioCentury | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
Items per page:
1 - 10 of 139